EARNING RECAP

ROKU Inc

#ROKU 2018 EPS:(Actual vs Estimate) Revenue(Actual vs Estimate) Stock price move next bell High Low Notes
Q4 5c est. 3c $275.74M est. $262.11M +25.23% ($64.47 closing price) $64.92 $54.50 sees Q1 revenue $185M-$190M est. $188.12M; sees FY19 revenue $1B- $1.02B; est $965.24M
Q3 (9c) est. (12c) $173.4M est. $169.08M -22.29% ($45.74 closing) $51.46 $45.62 sees Q4 revenue $255M- $265M est. $258.64M; Q3 active accounts up 43% at 23.8M; ARPU up 37% to $17.34
Q2 0c est. (15c) $156.8M est. $141.48M +21.31% ($57.32 closing) $57.95 $52.31 sees Q3 revenue $164M- $172M est. $165M; sees 2018 revenue $710M -$730M est. $697.93M
Q1 (7c) est. (15c) $136.6M est. $127.15M +8.94% ($36.08 closing) $36.95 $34 sees FY18 revenue $685M -$705M, net loss ($40M) to ($25M)
#ROKU 2017 EPS:(Actual vs Estimate) Revenue(Actual vs Estimate) Stock price move next bell High Low Notes
Q4 6c est. (10c) $188.3M est. $182.54M -17.71% ($42.05 closing) $44.33 $39.75 active acct. +44% YoYto 19.3M; sees Q1 revenue $120M -$130M, est. $131.71M,ebitda loss ($16M) to ($10M)
Q3 (10c) est. (28c) $124.7M vs $110.47M +54.94% ($29.19 closing) $29.44 $23.86 See Q4 REVENUE $175m-$190m VS $177.12M

Please select phase first
Disclaimer! This is NOT an investment advice. The data result herein is purely speculation only. You must do your own due diligence and mitigate your risk. You acknowledge that TradersFish.com will not be held responsible and accountable for any losses you may incur using our Biotech Data Calculator. Please consult your own financial adviser before executing trades.